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Abstract
Background: Adequate and intensive rehabilitation is an important requirement for successful Total Knee Arthroplasty. The
primary focus of early rehabilitation is ambulation of patients and regaining range of motion in the knee.
Although research suggests that Continuous Passive Motion should be implemented in the first rehabilitation phase following
surgery, there is substantial debate about the duration of each session and the total period of CPM application and. A Cochrane
review on this topic concluded that short-term use of CPM leads to greater short-term range of motion. It also suggested,
however, that future research should concentrate on the treatment period during which CPM should be administered.
Methods: In a randomised controlled trial we intend to investigate the efficacy of prolonged use of a continuous passive motion
(CPM) device in the home situation as an adjunct to standardised physical therapy. The experimental treatment is compared to
standardised physical therapy, in patients with osteoarthritis of the knee undergoing Total Knee Arthroplasty (TKA). Efficacy
will be assessed in terms of faster improvements in range of motion and functional recovery.
Seventy patients with knee osteoarthritis undergoing TKA and experiencing early postoperative flexion impairment (less than
80° of knee flexion at the time of discharge) will be randomised over two treatment groups, a usual care group and an
experimental group
The experimental group will receive CPM + physiotherapy for 17 consecutive days after surgery, whereas the usual care group
will receive the same treatment during the in-hospital phase (i.e. about four days), followed by physical therapy alone (usual care)
in the first two weeks after hospital discharge.
From 18 days to three months after discharge, both groups will receive standardised PT. The primary focus of rehabilitation will
be functional recovery (e.g. ambulation) and regaining range of motion (ROM) in the knee.
Discussion: Because restricted knee ROM affects functional activities, knee ROM and knee function are regarded as the
primary indicators of successful TKA. Potential effects of the intervention under study include rapid return of knee flexion
accompanied by earlier return to functional activities of daily life. If patients benefit significantly from prolonged CPM use, this
treatment should be added to the standard PT treatment at home.
We expect the additional home CPM programme to be more effective than the usual physiotherapy programme, resulting in a 
difference in ROM of at least 5°, 17 days after surgery. This clinically important difference, with a possible flexion ROM of about 
100°, is expected to lead to better functioning in activities of daily life, like walking, and earlier ability to cycle. These advantages 
should result in earlier and increasing independence.
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Background
With the ageing of the population, the prevalence of
degenerative joint diseases is increasing. Reports show
that over a one-year period, 25% of people over 55 years
have a persistent episode of knee pain, of whom annually
about one in six consult their general practitioner, in both
the UK and the Netherlands. The prevalence of painful
disabling knee osteoarthritis in people over 55 years is
10%, of whom one quarter are severely disabled. In all,
over 300,000 Dutch residents currently suffer from knee
osteoartritis (OA). Total Knee Arthroplasty (TKA) is a
common intervention that can enhance the quality of life
for patients with knee OA. Over 7500 TKAs are performed
in Dutch hospitals every year. In 2003, 160 TKAs were per-
formed at the Maastricht University Hospital.
Adequate and intensive rehabilitation is an important
requirement for successful TKA. The primary focus of early
rehabilitation is ambulation and regaining range of
motion (ROM) in the knee. Because restricted knee ROM
affects functional activities, knee ROM is regarded as one
of the primary indicators of a successful TKA. Rapid return
of knee flexion accompanied by earlier return to func-
tional activities of daily life is one of the potential effects
of the intervention we are proposing to study.
Although research findings favour the use of Continuous
Passive Motion (CPM) in the first rehabilitation phase fol-
lowing surgery [1-4], there is substantial debate about the
total period of CPM application and the duration of indi-
vidual sessions. A Cochrane review [1] on the topic con-
cluded that short-term use of CPM leads to a more rapid
recovery of rabnge of motion. It also suggested, however,
that future research should concentrate on the period dur-
ing which CPM should be administered, and therefore
called for research into longer-term use, involving long-
term follow-up.
Before the year 2000, discharge from the Maastricht Uni-
versity Hospital after TKA was scheduled approximately
14 days after surgery. Nowadays, most patients are dis-
charged four days after surgery. Since the time spent in
hospital following surgery has decreased, continuation of
CPM after hospital discharge might be beneficial.
Although CPM is increasingly being administered in the
postclinical home situation in recent years and is begin-
ning to become part of the usual care programme, proper
research into the effectiveness of a prolonged use of CPM
at home is still lacking [1,2]. The only study that has been
reported [5] compared CPM with physical therapy (PT) as
a stand-alone therapy, whereas in the study presented
here, CPM will be added to a standardised programme,
adequately reflecting current practice.
This study is expected to provide new insights into the
additional effects of CPM and to provide evidence to jus-
tify or refute its use.
Currently, orthopaedic surgeons at the hospital and phys-
iotherapists at the hospital and at home play an important
role in the rehabilitation process for TKA patients. The
proposal presented here involves the same health care
professionals and the same treatment strategies currently
in use, but one patient group will additionally receive
CPM at home.
We expect the effect of CPM treatment to be a quicker res-
toration of ROM, resulting in improved ADL function
during the first 3 months after surgery.
Knee flexion values of 95° and 105° are regarded as range
of motion benchmarks [6] in the functional recovery fol-
lowing CPM. While 95° of knee flexion allows normal
ADL function, 105° of flexion gives a person the opportu-
nity to ride a bicycle. This is of great advantage both in
daily life (at least in the Netherlands) and in the rehabili-
tation from TKA surgery, because cycling allows patients
to move the knee much more. We expect that prolonged
use of CPM at home will allow patients to achieve these
ROM benchmarks earlier in their recovery process.
About 50% of the patients undergoing one of the 160
TKAs performed annually at the Maastricht University
Hospital have less than 80° of flexion 4 days after surgery
and therefore potentially meet the inclusion criteria of the
proposed study.
If the study should find that patients benefit from home
CPM, this treatment should be added to the standard PT
treatment currently administered. No differences in direct
costs of rehabilitation are expected from implementation
of the study results.
Objective
Continuous passive motion (CPM) has proved to increase
the amount of knee flexion for knee patients in the acute
hospital setting (5–10 days). The primary purpose of the
proposed randomised controlled trial is to establish
whether there is additional long term benefit of continu-
ing CPM after hospital discharge.
Research question
What is the effect on range of motion and functional sta-
tus of prolonged use of a continuous passive motion
device at home in addition to physical therapy, compared
to physical therapy alone, in patients with limited flexion
range of motion (less than 80°) of the knee at discharge
from the hospital following total knee arthroplasty?BMC Musculoskeletal Disorders 2006, 7:15 http://www.biomedcentral.com/1471-2474/7/15
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Methods/Design
Study design
The proposed study is a randomised controlled trial, with
blinded treatment allocation, assessment and analysis, in
which 70 patients undergoing a scheduled unilateral TKA
will be evaluated to assess the added value of CPM at
home, using function and mobility as the main outcomes.
Participants
We intend to include 70 patients in the study, who must
be eligible for unilateral primary TKA as a result of oste-
oarthritis of the knee. Patients will be included if they
have less than 80° of flexion range of motion 4 days after
surgery, are able to understand and speak Dutch, are not
suffering from mental disabilities and are resident inside
the 'Maastricht heuvelland' region. Patients will be
excluded if they need to stay in hospital for more than 5
days after surgery or show relevant co-morbidity influenc-
ing mobility (e.g. claudication, other prosthesis) or are
operated upon using minimally invasive surgery.
Eligible patients will be contacted one week before
planned surgery, and will be randomised into two groups
after signing an informed consent form, on the day they
are discharged from hospital. Patients will thus have 10
days in which to consider participation.
Blocked and concealed randomisation with a block size of
4 will ensure equal distribution of patients over the two
treatment groups. Groups will be prestratified on preoper-
ative flexion mobility of the knee.
Interventions
During the in-hospital period, all patients will receive a
standardised PT programme, involving 20 minutes of PT
per day for four days. During the first two weeks after dis-
charge, patients in the experimental group will receive
CPM for 4 hours a day in addition to regular PT treatment.
Patients in the control group will receive only regular PT
treatment (usual care).
From day 18 onward, all patients will receive regular PT
treatment until 3 months after surgery, if indicated.
The post-clinical PT will be standardised in terms of treat-
ment objectives. All patients will receive treatment con-
sisting of active and passive mobilisation of the knee
joint, active strengthening of the m. quadriceps, and train-
ing of ADL functions (gait, sit to stand and stair climbing).
Outcome assessment
After baseline variables have been collected, outcome
measures will be assessed at 17 days, 6 weeks and 3
months after surgery, during normal routine assessments
at the orthopaedic clinic (table 1). The outcome assessor
will be blinded.
Primary outcome measures are:
1. functional status, using the WOMAC function score
[7,8] and the Knee Society Score[9]; and
2. range of motion, assessed with a long-arm goniometer
[10].
Secondary outcome measures are:
a. perceived effect, using a 7-point Likert scale;
b. postoperative medication use (amount; type will be
standardised);
c. satisfaction with treatment, on an 11-point Likert scale;
Table 1: Timing of the outcome assessment
T0 Pre-operative T1 Clinical phase T2 17 days after surgery T3 6 weeks after 
surgery
T4 12 weeks after 
surgery
Range of motion X X X X X
Knee Society Score X X X X X
WOMAC X X X X
Perceived effect X X X
Pain medication X X X X
Satisfaction with treatment X X X
Satisfaction with results X X X
Compliance X
Quantity, duration and kind of 
treatment
XX XBMC Musculoskeletal Disorders 2006, 7:15 http://www.biomedcentral.com/1471-2474/7/15
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d. satisfaction with treatment result, on an 11-point Likert
scale;
e. adherence to treatment protocols and use of CPM (in
hours), measured with a patient diary;
f. quantity, duration and nature of PT intervention.
The study design is depicted in figure 1
The first primary endpoint of the study is on day 17 after
surgery, which is when the experimental treatment stops
and short-term effects are measured.
The second endpoint is at 3 months after surgery.
Table 1 shows the timing of the outcome assessment
Power analyses
We assume a difference of more than 5° of knee flexion
mobility (SD 8°) at the end of the CPM application to be
clinically relevant. With an alpha of 0.05, and a power of
80%, we will need 28 patients per group to prove this.
Data analysis
Data will be stored and analysed with SPSS-12.0 After
checks for missing values and for normality of the data,
regression techniques will be applied by a blinded analyst
using the 'intention-to-treat' principle. Primary and sec-
ondary outcome measures will be reported for the in-hos-
pital and home situations, and for 6-week and 3-month
follow-up.
The primary research question will be tested using Stu-
dent's t-tests with a p-value of 0.05 being regarded as sig-
nificant.
Discussion
Dissemination
The results of this trial are expected to provide evidence
and clinically relevant information of direct use to profes-
sionals working in the field of rehabilitation after TKA
(orthopaedic surgeons, general practitioners, physical
therapists, occupational therapists and nurses). If the
additional use of CPM proves efficacious, CPM should be
administered to the target population. Therefore, health
insurance companies and public health services should
take note of the results and implement the findings in
their activities.
The results of the research will be disseminated by means
of publications in peer-reviewed scientific journals, by
updating the Dutch arthrosis guidelines for GPs and phys-
ical therapists, by publication of a PhD thesis and by
menas of lectures and presentations at conferences.
The relevant parties that can assure proper dissemination
of the research findings are to a large extent represented in
the project group. The orthopaedic surgeons are involved
in drawing up the osteoarthritis guidelines, the research
physical therapist and the project leader are responsible
for the osteoarthritis guidelines for physical therapists,
and the PhD student and promotion team are responsible
for the scientific dissemination of the results. The patients
with osteoarthritis receiving TKA surgery will receive
updated information through an updated leaflet, made
available at the hospital.
Ethics
Patients will be asked to participate in the study one week
prior to the planned surgery date. They will receive verbal
and written information on the study. After doing so, they
will have a 10-day period in which to decide whether or
study design Figure 1
study design. Legend to figure 1: T0 one week before surgery. T1 4 days after surgery. T2 17 days after surgery. T3 6 weeks 
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not to participate. Patients will be informed about the
option to end their participation in the study at any time.
An independent physician will be appointed to whom
patients can turn if they have any questions, etc. Written
consent will be asked prior to participation. All data will
be collected by a research assistant and will be stored in a
database. The data will be anonymised and coded so third
parties will not be able to link data to specific patients,
thus ensuring complete confidentiality of data of individ-
ual patients. After conclusion of the study, all participants
will be informed of the outcome.
Risks of participation
We believe there is very little additional risk for the partic-
ipants included in the CPM treatment group. All patients
will be familiar with the use of CPM device at the time
they are discharged from the hospital. Nevertheless we
have taken out supplementary insurance for all partici-
pants in the study.
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